Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil

Transplantation

Volumn 80, Issue 9, 2005, Pages 1174-1180

  Funch, Donnie P ^a   Hnin, Hnin Ko ^a   Travasso, Jacqueline ^a   Brady, Joanne ^a   Kew II, Clifton E ^b   Nalesnik, Michael A ^c   Walker, Alexander M ^a  

^a Ingenix Inc   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Case control study; Mycophenolate mofetil; Posttransplant lymphoproliferative disorder

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

AGE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFORMATION PROCESSING; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT FAILURE; UNITED STATES;

CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MYCOPHENOLIC ACID; ODDS RATIO; RISK ASSESSMENT;

EID: 28544450172     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000169035.10572.c6     Document Type: Article

References (27)

1. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: Summary of Society of Hematology Workshop. Semin Diagn Pathol 1997; 14: 8.
2. Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 1995; 46: 381.
3. Swerdlow SH. Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Semin Diagn Pathol 1997; 14: 2.
4. Penn I. The role of immunosuppression in lymphoma formation. Springer Semin Immunopathol 1998; 20: 343.
5. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003; 76: 984.
6. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1998; 133: 173.
7. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623.
8. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723.
9. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001; 3: 70.
10. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222.
11. Vanrenterghem Y. The use of mycophenolatemofetil (CellCept) in renal transplantation. Nephron 1997; 76: 392.
12. Sollinger HW. Mycophenolate mofetil for prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225.
13. Tricontinental Mycophenolate Mofetil Transplant Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
14. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405.
15. Kremers HM, Funch DP, Robson RA, et al. A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients. Pharmacoepidemiol Drug Saf 1999; 8: 509.
16. Funch DP, Brady J, Ko HH, et al. Recent incidence and case characteristics of post transplant lymphoproliferative disorder (PTLD) among renal transplant patients in the U.S. Pharmacoepidemiol Drug Saf 2001; 10: S38.
17. Morrison VA, Dunn DL, Manivel JC, et al. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994; 97: 14.
18. Nalesnik MA. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002; 159: 9.
19. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin. Oncol 1995; 13: 961.
20. Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002; 6: 396.
21. Birkeland SA, Andersen HK, Hamilton-Dutoit SJ. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. Transplantation 1999; 67: 1209.
22. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530.
23. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003; 76: 597.
24. Shihab FS, Bennett WM, Yi H, et al. Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity. Am J Transplant 2003; 3: 1550.
25. Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985; 152: 876.
26. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14: 214.
27. Boubenider S, Hiesse C, Goupy C, et al. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol 1997; 10: 136.